CD19 CAR-T Cell Therapy! The bait-merliso-cel review was again postponed by the FDA: Treatment of B-cell lymphoma is more safe!
The first BTK inhibitor to treat immunoplate plateroid reduction (ITP)! FDA grants Sanofi rilzabrutinib fast track eligibility!
New medicine for rare diseases! C3 inhibitor pegcetacoplan received FDA priority review: Phase 3 efficacy beats heavyweight C5 inhibitor Soliris
Nodding itch new drug! FDA grants OSMR beta-targeted blocking monoantigen vixarelimab breakthrough drug eligibility!